
Sign up to save your podcasts
Or


The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
Read this story here.
By WIRED4.3
5858 ratings
The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
Read this story here.

90,992 Listeners

32,287 Listeners

177 Listeners

102 Listeners

49 Listeners

61 Listeners

77 Listeners